In-transit disease is defined as any dermal or subcutaneous metastases that arise between the primary melanoma but not beyond the draining regional nodal basin. Patients who develop in-transit disease are at further risk to develop additional locoregional and distant disease. Treatment must be individualized and take into consideration the extent of disease, tumor characteristics, and patient characteristics including age, comorbidities, previous therapies, and site of recurrence. Surgery, regional perfusions and intralesional injections all play a role in management options. These patients should be discussed and managed by a multidisciplinary team whenever possible.
Keywords: Hyperthermic isolated limb perfusion; Intra-tumoral injections; Isolated limb infusion; Locoregional recurrence; Melanoma.
Copyright © 2014 Elsevier Inc. All rights reserved.